Extension Study of Long-term Safety and Efficacy of Tulisokibart
Phase 3
1,380
about 13 years
All ages
12 sites in CT, MI, MO +4
About this study
Researchers are testing the safety and effectiveness of tulisokibart over a long period in people with Crohn's disease or ulcerative colitis. The trial is for people who previously received tulisokibart in other studies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo to tulisokibart
- 2.Take Tulisokibart
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: Percentage of Participants with Crohn's Disease Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score
Gastroenterology